Workshop. Todd Anderson MD / Jacques Genest MD
|
|
- Hilda Fowler
- 5 years ago
- Views:
Transcription
1 Workshop Todd Anderson MD / Jacques Genest MD
2 Game-Changing Trials 2017 FOURIER Evolocumab n=27,564 HR 0.80 CANTOS Canakinumab n=10,061 HR 0.85 COMPASS Rivaroxaban + ASA n=27,395 HR 0.76 Key Secondary Endpoint CV Death, MI, or Stroke 10% 9% 8% 7% 6% 5% 4% 3% Hazard ratio 0.80 (95% CI, ) P< Placebo Evolocumab 9.9% 7.9% 2% 1% 0% Months from Randomization An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School Clinicians are faced with clinical trial data that supports targeting LDL-C, inflammation and thrombosis.
3 CANTOS: MACE + Cumulative incidence HR: 0.83 (95%CI: ) p=0.006* Placebo A 60 yo man with stable ASCVD has a residual FOURIER 14.6 risk / 3 yrs of 3%/year (CV Death, MI, stroke) and 5% risk of Canakinumab MACE+ 150 / 300 mg No. at Risk Years Placebo Canakinumab
4 Rapsomaniki E 2016
5 Residual Cardiovascular Risk A 62 yo. Man with stable ASCVD (MI one year ago;; PCI to LAD);; preserved LVEF. Non diabetic. BP 125/80 LDL-C 1.80 mmol/l 1. What is the life expectancy?* 2. What is the likelihood of a MACE+ in the next 5-10 years?
6 Life Expectancy Canada 2007 to 2009 Males Females Canada Newfoundland and Labrador Prince Edward Island Nova Scotia New Brunswick Quebec Ontario Manitoba Saskatchewan Alberta British Columbia Source: Statistics Canada, CANSIM, table and Catalogue no XIE.
7 Life Expectancy of a 60 yo Canadian Life expectancy (Female): 24.3 years Life expectancy (Male): 21.3 years Leading cause of death: Cancer
8 Precision-Guided Personalized Medicine Can we reliably identify biomarkers of residual cardiovascular risk that can guide therapy and improve outcomes? Metabolic: Inflammation LDL-C hscrp Non HDL-C IL-6 Apo B Imaging Lp(a) Glucose Blood pressure Thrombosis? Structural PAD LV function EP markers CMR markers
9 Which Medication, for how Long? Can we reliably identify biomarkers of residual cardiovascular risk that can guide duration of therapy and improve outcomes? Lipids: Likely lifelong Inflammation If the storm abates? Thrombosis?
10 Residual Cardiovascular Risk A 62 yo. Man with stable ASCVD (MI one year ago;; PCI to LAD);; preserved LVEF. Non diabetic. BP 130/80 LDL-C 2.50 mmol/l on maximally tolerated statin and ezetimibe
11 Residual Cardiovascular Risk A 62 yo. Man with stable ASCVD (MI 2014;; PCI to LAD);; preserved LVEF. Non diabetic. BP 135/85 LDL-C 1.80 mmol/l on maximally tolerated statin and ezetimibe. Recurrent PCIs since 2014 Would your recommendation be different if he had documented PAD and claudication
12 Residual Cardiovascular Risk A 62 yo. Woman with stable ASCVD (MI one year ago;; PCI to LAD);; preserved LVEF. Diabetic;; HgA1c 8.5., creatinine 124;; BP 130/85 LDL-C 2.50 mmol/l on maximally tolerated statin (rosuva 5 mg/day) and ezetimibe 10 mg per day
13 Residual Cardiovascular Risk A 42 yo. East Indian man with 4 th admission with ACS. Multiple PCI (LAD, Cx;; ISR Cx, PDA x2;; last one 2 years ago). Preserved LVEF. Diabetic;; creatinine 74;; BP 132/78 ASA 80;; Atorva 80;; Metformin ;; LDL-C 1.50 mmol/l HgA1c 5.5 Are there biomarkers that can guide therapy?
14 Residual Cardiovascular Risk A 62 yo. Woman with ischemic CMP (MI 10 years ago;; multiple admission in ACS and revascularization) LVEF 32%;; no viable myocardium (MRI). Diabetic;; creatinine 154;; BP 100/85. NYHA 2 Metformin ;; Gliclazide 30 2 ;; Bisoprolol 2.5;; Ramipril ;; ASA 80;; Sitagliptin 50;; rosuvastatin 10 LDL-C 2.50 mmol/l HgA1c 8.5 What are the priorities of treatment, do preventive measures matter?
15
16 PAD Patients in COMPASS PAD Groups Number of patients All Patients 7,470 Symptomatic PAD Limbs 4,129 Carotid Disease 1,919 CAD + Low ABI (<0.90) only 1,422 Mean Follow- up: 21 months
17 August 11, 2017 Primary outcome & components Outcome R + A N=2,492 N (%) R N=2,474 N (%) A N=2,504 N (%) Riva + aspirin vs. aspirin HR (95% CI) P Riva vs. aspirin HR (95% CI) P MACE 126 (5.1) 149 (6.0) 174 (6.9) 0.72 ( ) ( ) 0.19 MI 51 (2.0) 56 (2.3) 67 (2.7) 0.76 ( ) ( ) - Stroke 25 (1.0) 43 (1.7) 47 (1.9) 0.54 ( ) ( ) - CV Death 64 (2.6) 66 (2.7) 78 (3.1) 0.82 ( ) ( ) -
18 Limb outcomes Outcome R + A N=2,492 N (%) R N=2,474 N (%) A N=2,504 N (%) Riva + aspirin vs. aspirin HR (95% CI) P Riva vs. aspirin HR (95% CI) P MALE 30 Major amputation (1.2) 5 (0.2) 35 (1.4) 8 (0.3) 56 (2.2) 17 (0.7) 0.54 ( ) 0.30 ( ) ( ) 0.46 ( ) Aug 11, 2017
19 August 14, 2017 Key Composite Outcome Outcome R + A N=2,492 N (%) R N=2,474 N (%) A N=2,504 N (%) Riva + aspirin vs. aspirin HR (95% CI) P Riva vs. aspirin HR (95% CI) P MACE, MALE or Major amputation 157 (6.3) 188 (7.6) 225 (9.0) 0.69 ( ) ( ) 0.08
20 MACE or MALE or Major Amputation Cumulative Hazard Rate Aspirin Rivaroxaban Rivaroxaban + Aspirin Rivaroxaban + Aspirin vs. Aspirin HR: 0.69 ( ) P= Rivaroxaban vs.aspirin HR: 0.84 ( ) P= No. at Risk Year Riva + ASA Riva ASA
21 Major bleeding Outcome R + A N=2,492 N (%) R N=2,474 N (%) A N=2,504 N (%) Riva + aspirin vs. aspirin HR (95% CI) P Riva vs. aspirin HR (95% CI) P Major Bleeding Fatal Non- Fatal ICH Non- fatal other critical organ* 77 (3.1) 4 (0.2) 4 (0.2) 13 (0.5) 79 (3.2) 5 (0.2) 3 (0.1) 18 (0.7) 48 (1.9) 3 (0.1) 8 (0.3) 8 (0.3) 1.61 ( ) ( ) ( ) ( ) 0.06 * symptomatic
22 August 14, 2017 Net clinical benefit in PAD Outcome R + A N=2,492 R N=2,474 A N=2,504 Riva + aspirin vs. aspirin N (%) N (%) N (%) HR (95% CI) P Riva vs. aspirin HR (95% CI) P Net Clinical Benefit 169 (6.8) 207 (8.4) 234 (9.3) 0.72 ( ) ( ) 0.23
23 From CRP to IL- 6 to IL- 1: Moving Upstream to Identify Novel Targets for Atheroprotection Canakinumab Ridker ESC 2017 Ridker PM. Circ Res 2016;118:
24 Canakinumab Anti- Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10, Countries April June Primary Events Randomized Canakinumab 50 mg SC q 3 months Randomized Canakinumab 150 mg SC q 3 months Randomized Canakinumab 300 mg SC q 3 months* Randomized Placebo SC q 3 months Primary CV Endpoint: Nonfatal MI, Nonfatal Stroke, Cardiovascular Death (MACE) Key Secondary CV Endpoint: MACE + Unstable Angina Requiring Unplanned Revascularization (MACE+) Critical Non-Cardiovascular Safety Endpoints: Cancer and Cancer Mortality, Infection and Infection Mortality Ridker ESC 2017
25 Characteristic CANTOS - Baseline Clinical Characteristics Placebo (N=3347) Canakinumab SC q 3 months 50 mg (N=2170) 150 mg (N=2284) 300 mg (N=2263) Age (years) Female (%) Current smoker (%) Diabetes (%) Lipid lowering therapy (%) Renin- angiotensin inhibitors (%) Prior Revascularization (%) LDL cholesterol (mg/dl) HDL cholesterol (mg/dl) Triglycerides (mg/dl) hscrp (mg/l) Ridker ESC 2017
26 CANTOS: Primary Clinical Outcome Effects on MACE and MACE + Canakinumab SC q 3 months Primary Endpoint IR (per 100 person years) HR 95%CI P Secondary Endpoint IR (per 100 person years) HR 95%CI P Placebo (N=3347) (referent) (referent) (referent) (referent) 50 mg (N=2170) mg (N=2284) * * 300 mg (N=2263) P- trend *Statistically significant, adjusted for multiplicity, in accordance with the pre-specified closed-testing procedures Ridker ESC 2017
27 Endpoint CANTOS: Consistency of HRs Across All Cardiovascular Endpoints Placebo (N=3347) Canakinumab SC q 3 months 50 mg (N=2170) 150 mg (N=2284) 300 mg (N=2263) P- trend Primary Secondary Myocardial Infarction Urgent Revascularization Any Coronary Revascularization <0.001 Stroke Cardiac Arrest CV Death All Cause Mortality Ridker ESC 2017
28 Adverse Event CANTOS: Additional Outcomes (per 100 person years of exposure) Placebo (N=3347) Canakinumab SC q 3 months 50 mg (N=2170) 150 mg (N=2284) 300 mg (N=2263) P- trend Any SAE Leukopenia Any infection Fatal infection /0.02* Injection site reaction Any Malignancy Fatal Malignancy Arthritis Osteoarthritis Gout ALT > 3x normal Bilirubin > 2x normal Ridker ESC 2017 * P-value for combined canakinumab doses vs placebo
29 % LDL-C reduction and events in Jupiter study Ridker et al. EHJ subjects randomized to Rosuvastatin 20 mg 46% obtained a > 50% reduction in LDL-C
30 Ongoing Outcome Trials with PCSK9 Inhibitors Study FOURIER ODYSSEY OUTCOMES SPIRE- 1/ SPIRE- 2 Treatment Evolocumab: 420 mg QM or 140 mg Q2W Background: optimal lipid lowering therapy Alirocumab: 75 mg Q2W (up titrated to 150 mg Q2W if LDL >1.3 mmol/l;; down titrated if LDL <0.65 mmol/l) Background: optimized lipid lowering therapy Bococizumab: 150 mg Q2W Background: lipid lowering therapy Population MI or stroke ( last 4 weeks) OR PAD (plus Risk factors for CVD) Patients hospitalized for ACS (<12 months before randomization) Patients at high risk of a CV event # patients 27,500 18,000 SPIRE-1: 17,000 SPIRE-2: 9,000 LDL-C for eligibility LDL-C 1.8 mmol/l (or non- HDL-C 2.6 mmol/l) after 4 week stabilization with optimal lipid lowering therapy 1.8 mol/l or non-hdl-c 2.6 mmol/l SPIRE-1: LDL-C 1.8 and <2.6 mmol/l SPIRE-2: LDL-C 2.6 mmol/l or non-hdl-c 3.4 mmol/l Estimated study completion 2017 December 2017 SPIRE-1:June 2018 SPIRE-2: March 2018 ACS: acute coronary syndrome; CAD: coronary artery disease; CHD: coronary heart disease; CVD: coronary vascular disease; EZE: ezetimibe; FH:Familial Hypercholesterolemia; HeFH: Heterozygous Familial Hypercholesterolemia; PAD: peripheral- artery disease; T2DM: type 2 diabetes mellitus. clinicaltrials.gov accessed August 25, 2015.
31 FOURIER Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk MS Sabatine, RP Giugliano, AC Keech, N Honarpour, SM Wasserman, PS Sever, and TR Pedersen, for the FOURIER Steering Committee & Investigators American College of Cardiology 66 th Annual Scientific Session Late- Breaking Clinical Trial March 17, 2017
32 Trial Design 27,564 high-risk, stable patients with established CV disease (prior MI, prior stroke, or symptomatic PAD) Screening, Lipid Stabilization, and Placebo Run-in High or moderate intensity statin therapy (± ezetimibe) LDL-C 70 mg/dl or non-hdl-c 100 mg/dl Evolocumab SC 140 mg Q2W or 420 mg QM RANDOMIZED DOUBLE BLIND Placebo SC Q2W or QM Follow-up Q 12 weeks Sabatine MS et al. Am Heart J 2016;;173:94-101
33 Endpoints Efficacy Primary: CV death, MI, stroke, hosp. for UA, or coronary revasc Key secondary: CV death, MI or stroke Safety AEs/SAEs Events of interest incl. muscle- related, new- onset diabetes, neurocognitive Development of anti- evolocumab Ab (binding and neutralizing) TIMI Clinical Events Committee (CEC) Adjudicated all efficacy endpoints & new- onset diabetes Members unaware of treatment assignment & lipid levels Sabatine MS et al. Am Heart J 2016;;173:94-101
34 Baseline Characteristics Characteristic Value Age, years, mean (SD) 63 (9) Male sex (%) 75 Type of cardiovascular disease (%) Myocardial infarction 81 Stroke (non- hemorrhagic) 19 Symptomatic PAD 13 Cardiovascular risk factor (%) Hypertension 80 Diabetes mellitus 37 Current cigarette use 28 Median time from most recent event ~3 yrs Pooled data;; no differences between treatment arms
35 Lipid Lowering Therapy & Lipid Levels at Baseline Characteristic Statin use (%)* Value High- intensity 69 Moderate- intensity 30 Ezetimibe use (%) 5 Median lipid measures (IQR) mg/dl LDL- C Total cholesterol HDL- C Triglycerides *Per protocol, patients were to be on atorva 20 mg/d or equivalent. 1% were on low intensity or intensity data were missing. Statin intensity defined per ACC/AHA 2013 Cholesterol Guidelines. 92 (80-109) 168 ( ) 44 (37-53) 133 ( ) Pooled data;; no differences between treatment arms
36 LDL Cholesterol Placebo LDL Cholesterol (mg/dl) % mean reduction (95%CI 58-60), P< Absolute reduction: 56 mg/dl (95%CI 55-57) Evolocumab (median 30 mg/dl, IQR mg/dl) Weeks An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School
37 Primary Endpoint CV Death, MI, Stroke, Hosp for UA, or Cor Revasc 16% 14% 12% 10% 8% 6% 4% 2% Hazard ratio % (95% CI, ) P< Placebo 12.6% Evolocumab 0% An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School Months from Randomization
38 Key Secondary Endpoint CV Death, MI, or Stroke 10% 9% 8% 7% 6% 5% 4% 3% Hazard ratio 0.80 (95% CI, ) P< Placebo Evolocumab 9.9% 7.9% 2% 1% 0% An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School Months from Randomization
39 Types of CV Outcomes Endpoint Evolocumab (N=13,784) Placebo (N=13,780) 3- yr Kaplan- Meier rate HR (95% CI) CV death, MI, or stroke ( ) Cardiovascular death ( ) Death due to acute MI ( ) Death due to stroke ( ) Other CV death ( ) MI ( ) Stroke ( )
40 Fatal or Nonfatal MI or Stroke 8% 19% RRR 8% 33% RRR Fatal or Nonfatal MI or Stroke 6% 4% 2% HR 0.81 (95%CI ) P=0.003 Placebo 6% 4% 2% HR 0.67 (95%CI ) P< Evolocumab 0% 0% Months from Randomization An Academic Research Organization of Brigham and Women s Hospital and Harvard Medical School
41 Safety Evolocumab (N=13,769) Placebo (N=13,756) Adverse events (%) Any Serious Allergic reaction Injection- site reaction Treatment- related and led to d/c of study drug Muscle- related Cataract Diabetes (new- onset) Neurocognitive Laboratory results (%) Binding Ab 0.3 n/a Neutralizing Ab none n/a New-onset diabetes assessed in patients without diabetes at baseline;; adjudicated by CEC
42 PCSK9 Inhibition and Very low LDL- C Giugliano et al. Lancet Aug 28, ,982 Fourier patients 4 week LDL-C Positive outcomes down to 0.2 mmol/l
43 PCSK9 Inhibition and Very low LDL- C Giugliano et al. Lancet Aug 28, ,982 Fourier patients 4 week LDL-C Positive outcomes down to 0.2 mmol/l Primary EP death, MI, revasc, hospitalization for UA
44
45
46
47
48
49
50 REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease ) A prospective, multi- center, randomized, open- label, blinded endpoint, physician- initiated trial to determine whether high- dose as compared with low- dose pitavastatin therapy within the approved dose range could reduce CV events in Japanese patients with stable CAD. Eligibility: Consent for enrollment Men and women, years of age Stable CAD: ACS or PCI/CABG >3 months Clinical diagnosis with coronary stenosis 50 % diameter stenosis LDL- C <120 mg/dl on pitavastatin 1 mg/day during the run- in period Pitavastatin 1 mg/day Randomization Pitavastatin 1mg/day Pitavastatin 4mg/day Jan LDL- C <120 mg/dl - Mar Jan.- Mar Run- in Period (>1 month) Follow- up (36-60 months) Pitavastatin 1 mg and 4 mg have LDL- C lowering effect comparable to atorvastatin 5 mg and 20 mg, respectively.
51 Baseline Characteristics Variables Pitavastatin 1 mg (N=6,214) Pitavastatin 4 mg (N=6,199) Age years 68.1± ±8.3 Male sex 82.5% 82.7% BMI kg/m ± ±3.3 Hypertension 75.4% 75.9% Diabetes mellitus 40.0% 40.2% Current smoking 15.9% 16.8% History of ACS 71.9% 71.8% ACS within 1 year before randomization 24.2% 24.1% Coronary revascularization 90.5% 90.4% Revascularization within 1 year before randomization 27.7% 27.7% Ischemic stroke 6.9% 6.8% Peripheral vascular disease 7.4% 6.6% CKD (egfr <60 ml/min/1.73m 2 ) 36.2% 35.4% Aspirin 92.5% 92.4% DAPT 44.6% 43.9%
52 Serial Changes in Lipid Parameters and hs-crp LDL-C (mg/dl) LDL-C 100 Pitavastatin 1 mg 55 Pitavastatin 4 mg Main effect p< Interaction p< Baseline No. of Patients 1mg 6,214 6,031 4mg 6,199 5,890 5,615 5,518 Years 5,252 5,203 4,509 4,405 HDL-C (mg/dl) No. of Patients 1mg 4mg ,212 6, ,028 5, ,596 5,482 HDL-C Years Main effect p< Interaction p= ,238 5, Baseline ,498 4,388 TG (mg/dl) No. of Patients 1mg 6,208 6,032 4mg 6,195 5, ,606 5,498 TG Years ,245 5, ,507 4,402 1mg 4mg hs-crp Main effect p< Interaction p= 0.77 Main effect p< Baseline Baseline 6 hs-crp (mg/l) No. of Patients ,032 5,994 Months ,734 5,585
53 Primary Endpoint Cumulative incidence(%) No. at risk 1mg 4mg 6,214 6,199 (CV death/mi/ischemic stroke/ UA) HR 0.81 (95% CI, ), Cox P=0.01 No. of patients with event: 4mg 266 (4.3%), 1mg 334 (5.4%) NNT for 5 years=63 Pitavastatin 1mg Pitavastatin 4mg log-rank P= Years ,743 5,321 4,501 2,760 5,631 5,256 4,427 2,
54 Secondary Endpoint Primary Endpoint plus Coronary Revascularization* Cumulative incidence(%) HR 0.83 (95% CI, ), Cox P=0.002 No. of patients with event: 4mg 489 (7.9%), 1mg 600 (9.7%) NNT for 5 years=41 Pitavastatin 1mg Pitavastatin 4mg 2.8 log-rank P= No. at risk Years 1mg 6,214 5,660 5,166 4,327 2,627 4mg 6,199 5,556 5,131 4,277 2,617 : Excluding TLR for lesions treated at prior PCI *
55 How did we get here? 55
56 PIONEER AF- PCI Study Design International, multicenter, randomized, open- label trial Inclusion Men and women at least 18 years of age Paroxysmal, persistent, or permanent nonvalvular AF Undergone PCI with stent placement Documented AF that occurred within 1 year before screening Exclusion History of stroke or TIA Clinically significant GI bleeding within 12 months before randomization CrCl<30 ml/min Anemia of an unknown cause with a Hgb <10 g/dl Any other condition known to increase the risk of bleeding N Engl J Med 2016; 375:
57 End Points Primary Safety Secondary TIMI Major Bleeding Safety Each component of the primary safety endpoint TIMI Minor Bleeding Bleeding Requiring Medical Attention Efficacy Major cardiovascular event composite* Stent thrombosis Clinically Significant Bleeding Exploratory ISTH Major bleeding GUSTO severe bleeding *Death from cardiovascular cause, MI, Stroke Each component of the composite N Engl J Med 2016; 375:
58 Treatment Subgroups 12 Months NVAF No Prior Stroke/TIA PCI with Stent Placement 72 hours After sheath removal R a n d o m iz a t i o n 1 month Rivaroxaban 15 mg Daily + Clopidogrel 75 mg 6 months Rivaroxaban 2.5 mg BID + DAPT Rivaroxaban 15 mg + ASA mg Rivaroxaban 15 mg + ASA mg Warfarin (INR ) + DAPT Warfarin + ASA mg 1 month *Rivaroxaban 10 mg daily if CrCl 30- <50 ml/min Prasugrel 10 mg daily or Ticagrelor 90 mg BID in <15% of patients N Engl J Med 2016; 375: months Warfarin + ASA mg 58
59 Statistical Analysis Analysis based on pooled data across all strata of DAPT duration (1, 6, or 12 months) Modified intention- to- treat analysis based on data for all participants who underwent randomized and received at least 1 dose of trial drug Intention- to- treat based on data obtained through follow- up of all participants who underwent randomization Comparisons of group 1 vs group 3 and group 2 vs group 3 were performed simultaneously with no adjustment for type I error at a rate of 0.05 N Engl J Med 2016; 375:
60 Patient Characteristics N Engl J Med 2016; 375:
61 Results Participants who received at least one dose of the trial treatment permanently discontinued the treatment before the scheduled termination date Group 1: 21.0% Group 2: 21.1% Group 3: 29.4% P<0.001 For both comparisons N Engl J Med 2016; 375:
62 N Engl J Med 2016; 375:
63 Results Group 1 Rivaroxaban 15 mg Daily + P2Y12 12 Months Group 2 Rivaroxaban 2.5 mg BID + DAPT 1,6,12 Month(s) Group 3 Warfarin + DAPT 1,6,12 Month(s) Primary Safety 16.8% HR:0.59;CI: ; P<0.001 Primary Safety 18.0% HR:0.63;CI: ; P<0.001 Primary Safety 26.7% Major Adverse Cardiovascular Event 6.5% HR:1.08;CI: ; P=0.75 Major Adverse Cardiovascular Event 5.6% HR:0.93;CI: ; P=0.76 Major Adverse Cardiovascular Event 6.0% N Engl J Med 2016; 375:
64 Results N Engl J Med 2016; 375:
65 Results N Engl J Med 2016; 375:
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationLDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationReducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationSanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California
Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationChanging Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events Deepak L. Bhatt, MD, MPH Executive Director Interventional Cardiovascular Programs Brigham and Women s Hospital
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More information2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty
Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology
More informationAntithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT
Antithrombotic Therapy for Long-Term Secondary Prevention Considerations for Long-Term DAPT Marc P. Bonaca, MD, MPH Vascular Section, Cardiovascular Division Investigator TIMI Study Group Brigham and Women
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationPreventing coronary artery disease: Cholesterol or inflammation?
Preventing coronary artery disease: Cholesterol or inflammation? Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationTHE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It? THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It?
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology and Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School and NYU Center for CV Prevention
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationLipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Michelle L. O Donoghue, Robert P. Giugliano, Anthony C. Keech, Estella Kanevsky, KyungAh Im, Peter S. Sever, Terje
More informationIndicações para um inibidor de PCSK9
Indicações para um inibidor de PCSK9 Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical Research Institute Duke University Medical Center 1987 2017: 30 years since first
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationTHIERS CHAGAS BAHIA FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR
FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR THIERS CHAGAS BAHIA Global Core Content: Do not copy or distribute. Placeholder for Regional/Local Disclaimer. CONFLITO DE
More informationREAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease
REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationPCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia
: 262-267, 2017 Περίληψη Διάλεξης PCSK9 antibodies: A new therapeutic option for the treatment of hypercholesterolemia I. Gouni-Bethold Polyclinic for Endocrinology, Diabetes, and Preventive Medicine University
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationLipids What s new? Meera Jain, MD Providence Portland Medical Center
Lipids 2016- What s new? Meera Jain, MD Providence Portland Medical Center 1 Can I trust the ASCVD risk calculator? Do harms outweigh benefits in primary prevention? Is there anything besides a statin?
More informationLipids: Guidelines & Best Treatment Options
Lipids: Guidelines & Best Treatment Options Michael Miller, MD, FACC, FAHA, FNLA Professor of Cardiovascular Medicine University of Maryland School of Medicine www.drmichaelmiller.org Michael Miller, MD,
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationNew Approaches to Lower LDL-C
New Approaches to Lower LDL-C CSIM 27 October 2016 Jacques Genest MD Cardiovascular Health Across the Lifespan Program McGill University Health Center Disclosure J. Genest MD 2016 Advisory Board, Speaker
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationInvestor Conference Call
Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery
More informationDr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου
Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy
More informationHyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine
Hyperlipidemia Guidelines: What s New in 2015? Eva Lonn, MD, MSc Professor of Medicine The new england journal of medicine Original Article Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More information